Beam Therapeutics Inc (BEAM) Is Now En Route to Higher Prices

Beam Therapeutics Inc (NASDAQ: BEAM) is -24.62% lower on its value in year-to-date trading and has touched a low of $16.95 and a high of $50.74 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BEAM stock was last observed hovering at around $28.07 in the last trading session, with the day’s gains setting it 1.41%.

Currently trading at $29.48, the stock is 3.75% and 18.46% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.85 million and changing 5.02% at the moment leaves the stock 4.02% off its SMA200. BEAM registered -31.81% loss for a year compared to 6-month loss of -7.79%. The firm has a 50-day simple moving average (SMA 50) of $19.13 and a 200-day simple moving average (SMA200) of -$4.11.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 0.03% gain in the last 1 month and extending the period to 3 months gives it a 28.12%, and is 3.73% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.22% over the week and 6.69% over the month.

Beam Therapeutics Inc (BEAM) has around 507 employees, a market worth around $2.40B and $81.55M in sales. Profit margin for the company is -384.62%. Distance from 52-week low is 73.92% and -41.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.37%).

Beam Therapeutics Inc (BEAM) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Beam Therapeutics Inc (BEAM) is a “Overweight”. 15 analysts offering their recommendations for the stock have an average rating of 2.07, where 8 rate it as a Hold and 0 think it is a “Overweight”. 7 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Beam Therapeutics Inc is expected to release its quarterly report on 02/27/2024.The EPS is expected to shrink by -2.11% this year.

Beam Therapeutics Inc (BEAM) Top Institutional Holders

The shares outstanding are 71.28M, and float is at 68.86M with Short Float at 18.88%.

Beam Therapeutics Inc (BEAM) Insider Activity

A total of 9 insider transactions have happened at Beam Therapeutics Inc (BEAM) in the last six months, with sales accounting for 5 and purchases happening 4 times. The most recent transaction is an insider sale by Bellon Christine,the company’sChief Legal Officer. SEC filings show that Bellon Christine sold 10,000 shares of the company’s common stock on Nov 20 at a price of $30.50 per share for a total of $0.3 million. Following the sale, the insider now owns 82402.0 shares.

Beam Therapeutics Inc disclosed in a document filed with the SEC on Oct 30 that Simon Amy (Chief Medical Officer) sold a total of 3,448 shares of the company’s common stock. The trade occurred on Oct 30 and was made at $18.70 per share for $64478.0. Following the transaction, the insider now directly holds 65469.0 shares of the BEAM stock.

Still, SEC filings show that on Oct 02, Bellon Christine (Chief Legal Officer) disposed off 388 shares at an average price of $22.85 for $8866.0. The insider now directly holds 82,402 shares of Beam Therapeutics Inc (BEAM).